Development of Ligands and Degraders Targeting MAGE-A3

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Type I melanoma antigen (MAGE) family proteins are expressed in various tumors, correlating with poor prognosis and metastasis.
• MAGE proteins regulate proteostasis via E3 ligase complexes, presenting therapeutic targets due to cancer-selective expression.
• Targeted MAGE degradation could enhance cancer antigen presentation, improving immunotherapy efficacy.

Purpose of the Study:

• To develop novel small-molecule ligands for MAGE-A3, a MAGE protein frequently found in tumors.
• To create Proteolysis-Targeting Chimeras (PROTACs) utilizing these ligands to induce MAGE-A3 degradation.
• To investigate the potential of MAGE-A3 ligands and PROTACs as cancer therapeutics and research tools.

Main Methods:

• DNA-encoded library (DEL) screening to identify small-molecule ligands for MAGE-A3.
• In vitro validation of hit compounds for MAGE-A3 binding.
• Cocrystallography to determine the binding mode of a DEL analog.
• Development of PROTAC molecules recruiting VHL for MAGE-A3 degradation.
• Assessment of PROTAC-induced MAGE-A3 degradation and inhibition of MAGE-A3 positive cell line proliferation.

Main Results:

• Novel small-molecule ligands for MAGE-A3 were identified via DEL screening and validated for binding.
• A cocrystal structure revealed the ligand binds at a MAGE-A3 dimer interface.
• PROTACs were successfully developed, inducing MAGE-A3 degradation through VHL recruitment.
• These PROTACs inhibited the proliferation of MAGE-A3 positive cancer cell lines.

Conclusions:

• Small-molecule ligands targeting MAGE-A3 were developed, serving as a foundation for targeted protein degradation strategies.
• PROTACs inducing MAGE-A3 degradation show promise for cancer therapy by inhibiting tumor cell growth.
• These findings support the use of MAGE-A3 ligands and degraders as tools for biological research and the development of novel cancer treatments.